Your browser is no longer supported. Please, upgrade your browser.
Settings
TARA Protara Therapeutics, Inc. daily Stock Chart
TARA [NASD]
Protara Therapeutics, Inc.
Index- P/E- EPS (ttm)-9.22 Insider Own10.40% Shs Outstand5.84M Perf Week-8.81%
Market Cap144.24M Forward P/E- EPS next Y-1.70 Insider Trans-6.59% Shs Float4.26M Perf Month-7.34%
Income-20.30M PEG- EPS next Q-0.50 Inst Own67.50% Short Float1.45% Perf Quarter-0.21%
Sales- P/S- EPS this Y34.20% Inst Trans- Short Ratio2.04 Perf Half Y-34.91%
Book/sh10.17 P/B2.36 EPS next Y48.60% ROA-54.30% Target Price- Perf Year110.23%
Cash/sh- P/C- EPS next 5Y- ROE-82.20% 52W Range8.80 - 67.08 Perf YTD46.34%
Dividend- P/FCF- EPS past 5Y24.90% ROI- 52W High-64.22% Beta0.95
Dividend %- Quick Ratio9.50 Sales past 5Y- Gross Margin- 52W Low172.73% ATR2.31
Employees8 Current Ratio9.50 Sales Q/Q- Oper. Margin- RSI (14)38.92 Volatility11.85% 9.07%
OptionableNo Debt/Eq0.02 EPS Q/Q88.70% Profit Margin- Rel Volume0.87 Prev Close24.61
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume30.23K Price24.00
Recom1.00 SMA20-7.46% SMA50-18.06% SMA200-5.93% Volume26,162 Change-2.48%
Jul-29-20Initiated Guggenheim Buy $50
Aug-03-20 07:00AM  
Jul-28-20 07:00AM  
Jul-24-20 07:00AM  
Jul-03-20 06:34PM  
Jul-02-20 07:59PM  
04:05PM  
Jun-02-20 04:05PM  
May-26-20 08:30AM  
May-13-20 08:00AM  
May-11-20 08:38AM  
May-05-20 04:05PM  
Apr-02-20 07:00AM  
Feb-11-20 08:00AM  
Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marshall Randall10% OwnerJul 30Sale26.141,31734,426611,180Jul 31 04:59 PM
Marshall Randall10% OwnerJul 29Sale26.422,51666,483612,497Jul 31 04:59 PM
Marshall Randall10% OwnerJul 28Sale30.5425,597781,797615,013Jul 29 04:40 PM
Marshall Randall10% OwnerJul 27Sale26.083388,815640,610Jul 29 04:40 PM
Marshall Randall10% OwnerJul 24Sale26.003007,800640,948Jul 27 04:07 PM
Marshall Randall10% OwnerJul 23Sale26.612,04354,369641,248Jul 27 04:07 PM
Marshall Randall10% OwnerJul 22Sale26.731,37236,675643,291Jul 23 04:31 PM
Marshall Randall10% OwnerJul 21Sale26.562235,923644,663Jul 23 04:31 PM
Marshall Randall10% OwnerJul 20Sale26.872,72973,327644,886Jul 21 04:44 PM
Marshall Randall10% OwnerJul 17Sale26.661,60142,683647,615Jul 21 04:44 PM
Marshall Randall10% OwnerJul 13Sale27.132,14558,194649,216Jul 14 04:40 PM
Marshall Randall10% OwnerJul 10Sale27.412,65972,883651,361Jul 14 04:40 PM